pitolisant 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5048 362665-56-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • HBS-101
  • pitolisant
  • tiprolisant
  • pitolisant hydrochloride
  • tiprolisant hydrochloride
  • wakix
  • BF2.649
Pitolisant is a potent, orally active histamine H3-receptor antagonist/inverse agonist which, via its blockade of histamine auto-receptors enhances the activity of brain histaminergic neurons, a major arousal system with widespread projections to the whole brain. Pitolisant also modulates various neurotransmitter systems, increasing acetylcholine, noradrenaline and dopamine release in the brain.
  • Molecular weight: 295.85
  • Formula: C17H26ClNO
  • CLOGP: 4.82
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 12.47
  • ALOGS: -5.32
  • ROTB: 8

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
18 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 31, 2016 EMA Bioprojet Pharma
Aug. 14, 2019 FDA HARMONY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Splenic infarction 113.80 50.21 18 377 1542 50603187

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Splenic infarction 113.63 50.82 18 229 3239 64495246

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07XX11 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
OTHER NERVOUS SYSTEM DRUGS
Other nervous system drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Narcolepsy indication 60380001 DOID:8986




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.59 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 17.8MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL 8354430 Feb. 6, 2026 METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
EQ 17.8MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL 8354430 Feb. 6, 2026 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
EQ 4.45MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL 8354430 Feb. 6, 2026 METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
EQ 4.45MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL 8354430 Feb. 6, 2026 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
EQ 17.8MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL 8486947 Sept. 26, 2029 METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
EQ 17.8MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL 8486947 Sept. 26, 2029 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
EQ 4.45MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL 8486947 Sept. 26, 2029 METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
EQ 4.45MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL 8486947 Sept. 26, 2029 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 17.8MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL Oct. 13, 2023 TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NACROLEPSY
EQ 4.45MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL Oct. 13, 2023 TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NACROLEPSY
EQ 17.8MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL Aug. 14, 2024 NEW CHEMICAL ENTITY
EQ 4.45MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL Aug. 14, 2024 NEW CHEMICAL ENTITY
EQ 17.8MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL Aug. 14, 2026 INDICATED FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN ADULT PATIENTS WITH NARCOLEPSY
EQ 4.45MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL Aug. 14, 2026 INDICATED FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN ADULT PATIENTS WITH NARCOLEPSY
EQ 17.8MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL Oct. 13, 2027 TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NACROLEPSY
EQ 4.45MG BASE WAKIX HARMONY N211150 Aug. 14, 2019 RX TABLET ORAL Oct. 13, 2027 TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NACROLEPSY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H3 receptor GPCR INVERSE AGONIST Ki 9.80 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Histamine H1 receptor GPCR Ki 5.94 CHEMBL
Histamine H2 receptor GPCR ANTAGONIST Ki 4.96 IUPHAR
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.77 CHEMBL
Histamine H3 receptor GPCR Ki 7.77 CHEMBL
Histamine H3 receptor GPCR Ki 7.85 CHEMBL
Histamine H3 receptor GPCR Ki 9.80 CHEMBL
Cholinesterase Enzyme IC50 5.08 CHEMBL

External reference:

IDSource
4BC83L4PIY UNII
903576-44-3 SECONDARY_CAS_RN
4038743 VANDF
4038744 VANDF
C3529928 UMLSCUI
CHEBI:134709 CHEBI
CHEMBL462605 ChEMBL_ID
9948102 PUBCHEM_CID
DB11642 DRUGBANK_ID
CHEMBL4164059 ChEMBL_ID
8952 INN_ID
C516975 MESH_SUPPLEMENTAL_RECORD_UI
8924 IUPHAR_LIGAND_ID
2197878 RXNORM
247019 MMSL
32128 MMSL
d08498 MMSL
421000220103 SNOMEDCT_US
716308007 SNOMEDCT_US
789360005 SNOMEDCT_US
017799 NDDF
017884 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Wakix HUMAN PRESCRIPTION DRUG LABEL 1 72028-045 TABLET, FILM COATED 4.45 mg ORAL NDA 29 sections
Wakix HUMAN PRESCRIPTION DRUG LABEL 1 72028-178 TABLET, FILM COATED 17.80 mg ORAL NDA 29 sections